Comprehensive control of human papillomavirus infections and related diseases

F. Xavier Bosch, Thomas R. Broker, David Forman, Anna Barbara Moscicki, Maura L. Gillison, John Doorbar, Peter L. Stern, Margaret Stanley, Marc Arbyn, Mario Poljak, Jack Cuzick, Philip E. Castle, John T. Schiller, Lauri E. Markowitz, William A. Fisher, Karen Canfell, Lynette A. Denny, Eduardo L. Franco, Marc Steben, Mark A. Kane & 10 others Mark Schiffman, Chris J L M Meijer, Rengaswamy Sankaranarayanan, Xavier Castellsagué, Jane J. Kim, Maria Brotons, Laia Alemany, Ginesa Albero, Mireia Diaz, Silvia de Sanjosé

Research output: Contribution to journalReview article

192 Citations (Scopus)

Abstract

Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.This article summarizes information from the chapters presented in a special ICO Monograph '. Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.

Original languageEnglish (US)
JournalVaccine
Volume31
Issue numberS5
DOIs
StatePublished - Dec 29 2013
Externally publishedYes

Fingerprint

Papillomavirus Infections
Papillomaviridae
infection
neoplasms
Uterine Cervical Neoplasms
uterine cervical neoplasms
Neoplasms
Developed Countries
screening
developed countries
Vaccination
vaccination
International Agencies
Papillomavirus Vaccines
vaccines
Uterine Neoplasms
Oropharynx
advocacy
Vulva
Molecular Pathology

Keywords

  • Anal cancer
  • Cervical cancer
  • HPV
  • HPV testing
  • HPV vaccination
  • Oropharyngeal cancer
  • Penile cancer
  • Prevention
  • Screening
  • Vaginal cancer
  • Vulvar cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Bosch, F. X., Broker, T. R., Forman, D., Moscicki, A. B., Gillison, M. L., Doorbar, J., ... Sanjosé, S. D. (2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 31(S5). https://doi.org/10.1016/j.vaccine.2013.10.001

Comprehensive control of human papillomavirus infections and related diseases. / Bosch, F. Xavier; Broker, Thomas R.; Forman, David; Moscicki, Anna Barbara; Gillison, Maura L.; Doorbar, John; Stern, Peter L.; Stanley, Margaret; Arbyn, Marc; Poljak, Mario; Cuzick, Jack; Castle, Philip E.; Schiller, John T.; Markowitz, Lauri E.; Fisher, William A.; Canfell, Karen; Denny, Lynette A.; Franco, Eduardo L.; Steben, Marc; Kane, Mark A.; Schiffman, Mark; Meijer, Chris J L M; Sankaranarayanan, Rengaswamy; Castellsagué, Xavier; Kim, Jane J.; Brotons, Maria; Alemany, Laia; Albero, Ginesa; Diaz, Mireia; Sanjosé, Silvia de.

In: Vaccine, Vol. 31, No. S5, 29.12.2013.

Research output: Contribution to journalReview article

Bosch, FX, Broker, TR, Forman, D, Moscicki, AB, Gillison, ML, Doorbar, J, Stern, PL, Stanley, M, Arbyn, M, Poljak, M, Cuzick, J, Castle, PE, Schiller, JT, Markowitz, LE, Fisher, WA, Canfell, K, Denny, LA, Franco, EL, Steben, M, Kane, MA, Schiffman, M, Meijer, CJLM, Sankaranarayanan, R, Castellsagué, X, Kim, JJ, Brotons, M, Alemany, L, Albero, G, Diaz, M & Sanjosé, SD 2013, 'Comprehensive control of human papillomavirus infections and related diseases', Vaccine, vol. 31, no. S5. https://doi.org/10.1016/j.vaccine.2013.10.001
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Dec 29;31(S5). https://doi.org/10.1016/j.vaccine.2013.10.001
Bosch, F. Xavier ; Broker, Thomas R. ; Forman, David ; Moscicki, Anna Barbara ; Gillison, Maura L. ; Doorbar, John ; Stern, Peter L. ; Stanley, Margaret ; Arbyn, Marc ; Poljak, Mario ; Cuzick, Jack ; Castle, Philip E. ; Schiller, John T. ; Markowitz, Lauri E. ; Fisher, William A. ; Canfell, Karen ; Denny, Lynette A. ; Franco, Eduardo L. ; Steben, Marc ; Kane, Mark A. ; Schiffman, Mark ; Meijer, Chris J L M ; Sankaranarayanan, Rengaswamy ; Castellsagué, Xavier ; Kim, Jane J. ; Brotons, Maria ; Alemany, Laia ; Albero, Ginesa ; Diaz, Mireia ; Sanjosé, Silvia de. / Comprehensive control of human papillomavirus infections and related diseases. In: Vaccine. 2013 ; Vol. 31, No. S5.
@article{30056aebd787410284f8a81a43a5cea9,
title = "Comprehensive control of human papillomavirus infections and related diseases",
abstract = "Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8{\%} were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.This article summarizes information from the chapters presented in a special ICO Monograph '. Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.",
keywords = "Anal cancer, Cervical cancer, HPV, HPV testing, HPV vaccination, Oropharyngeal cancer, Penile cancer, Prevention, Screening, Vaginal cancer, Vulvar cancer",
author = "Bosch, {F. Xavier} and Broker, {Thomas R.} and David Forman and Moscicki, {Anna Barbara} and Gillison, {Maura L.} and John Doorbar and Stern, {Peter L.} and Margaret Stanley and Marc Arbyn and Mario Poljak and Jack Cuzick and Castle, {Philip E.} and Schiller, {John T.} and Markowitz, {Lauri E.} and Fisher, {William A.} and Karen Canfell and Denny, {Lynette A.} and Franco, {Eduardo L.} and Marc Steben and Kane, {Mark A.} and Mark Schiffman and Meijer, {Chris J L M} and Rengaswamy Sankaranarayanan and Xavier Castellsagu{\'e} and Kim, {Jane J.} and Maria Brotons and Laia Alemany and Ginesa Albero and Mireia Diaz and Sanjos{\'e}, {Silvia de}",
year = "2013",
month = "12",
day = "29",
doi = "10.1016/j.vaccine.2013.10.001",
language = "English (US)",
volume = "31",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "S5",

}

TY - JOUR

T1 - Comprehensive control of human papillomavirus infections and related diseases

AU - Bosch, F. Xavier

AU - Broker, Thomas R.

AU - Forman, David

AU - Moscicki, Anna Barbara

AU - Gillison, Maura L.

AU - Doorbar, John

AU - Stern, Peter L.

AU - Stanley, Margaret

AU - Arbyn, Marc

AU - Poljak, Mario

AU - Cuzick, Jack

AU - Castle, Philip E.

AU - Schiller, John T.

AU - Markowitz, Lauri E.

AU - Fisher, William A.

AU - Canfell, Karen

AU - Denny, Lynette A.

AU - Franco, Eduardo L.

AU - Steben, Marc

AU - Kane, Mark A.

AU - Schiffman, Mark

AU - Meijer, Chris J L M

AU - Sankaranarayanan, Rengaswamy

AU - Castellsagué, Xavier

AU - Kim, Jane J.

AU - Brotons, Maria

AU - Alemany, Laia

AU - Albero, Ginesa

AU - Diaz, Mireia

AU - Sanjosé, Silvia de

PY - 2013/12/29

Y1 - 2013/12/29

N2 - Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.This article summarizes information from the chapters presented in a special ICO Monograph '. Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.

AB - Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.This article summarizes information from the chapters presented in a special ICO Monograph '. Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters.

KW - Anal cancer

KW - Cervical cancer

KW - HPV

KW - HPV testing

KW - HPV vaccination

KW - Oropharyngeal cancer

KW - Penile cancer

KW - Prevention

KW - Screening

KW - Vaginal cancer

KW - Vulvar cancer

UR - http://www.scopus.com/inward/record.url?scp=84890078274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890078274&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.10.001

DO - 10.1016/j.vaccine.2013.10.001

M3 - Review article

VL - 31

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - S5

ER -